Effect of glaucocalyxin B on the protein expressions of PTEN, Beclin1 and LC3 in a mouse model of transplanted cervical cancer, and its significance
Purpose: To determine the effect of glaucocalyxin B (GLB) on the protein expressions of PTEN, Beclin1 and LC3 in a mouse model of transplanted cervical cancer, and its significance.
Methods: A mouse model of transplanted cervical cancer was established in female BALB/C mice. The model mice were divided into control group, low-dose GLB group and high-dose GLB group. Mice in low-dose and high-dose groups were given intraperitoneal injection of low-dose GLB and high-dose GLB, respectively. The volume and weight of transplanted tumor were measured and compared between the two groups. Serum levels of CEA and CA125 were assayed by enzyme-linked immunosorbent assay (ELISA). The expressions of phosphatase and tensin homolog (PTEN), autophagy-related factor microtubule-associated protein-1 (Beclin-1), microtubule-associated protein 1 light chain 3 (LC3), apoptosis-related protein p53, and Bax were determined using SABC immunohistochemical operation.
Results: On days 5, 10 and 15, the volume and weight of transplanted tumor, and levels of CA125 and CEA in low- and high-dose GLB groups were significantly and dose-dependently lower than those in control group (p < 0.05). Results from immunohistochemistry showed that the protein expression levels of PTEN, Beclin-1, LC3, p53 and Bax were significantly and dose-dependently higher in low- and highdose GLB groups than in the control group (p < 0.05).
Conclusion: Glaucocalyxin B significantly and dose-dependently induces apoptosis of cervical cancer cells and inhibits their growth by regulating the protein expressions of PTEN, Beclin1 and LC3. Thus, glaucocalyxin B is a potential adjunct therapy in the management of cervical cancer.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.